Close-Out: Tiny Baxter Lobby Spend, In Q3 2023... Last of 5 In The Series.

As I said, these smaller ones have a historical device component not present in the major "pure pharma/bio-science" companies we covered over this past weekend. So they seek input on laws that generally don't concern pure pharma (like infusion pumps and cardiovascular implants).

And Baxter -- with important operational (and candidly, regulatory) challenges of its own, has greatly reduced its lobby spend over the past two years. That is more a function of deploying the dollars where they'll do the most good in the near term, than much of anything else. Here's that run-down, on the $440,000 of spend in the past quarter:

. . .Issues relating to drug pricing, home dialysis expansion, and ESRD reimbursement for Hemodialysis. . . .

Issues related to pharmaceutical pricing; Legislation to incentivize new technology for innovation in home dialysis (no current bill number). . . .

Issues relating to 340B Drug pricing, and device sterilization; Issues relating to safe mobility and issues relating to diabetic retinopathy; Issues relating to pandemic preparedness act; H. Res. 550 and H.R. 4421; Issues related to artificial intelligence technology in healthcare. . . .

Issues related to increasing funding for Strategic National Stockpile; Labor, Health, and Human Services appropriations. . . .

Taxation of multinational companies; Monitor tax reform proposal relating to corporate tax policies. . . .

Now you know. . . be excellent to one another, now and always.

नमस्ते